Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML

Acta Haematol (2012) 127 (3): 152–155.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure

David Gómez-Almaguer
Roxana Saldaña-Vázquez
Luz Tarín-Arzaga
Miguel Angel Herrera-Rojas
Alberto Vázquez-Mellado de Larracoechea
Olga Graciela Cantú-Rodríguez
Cesar Homero Gutiérrez-Aguirre
José Carlos Jaime-Pérez

Hematology (2016) 21 (7): 411.

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies

Ellen Weisberg
Atsushi Nonami
James D. Griffin

Archives of Toxicology (2014) 88 (12): 2233.

Update: The Status of Clinical Trials With Kinase Inhibitors in Thyroid Cancer

Samuel A. Wells
Massimo Santoro

The Journal of Clinical Endocrinology & Metabolism (2014) 99 (5): 1543.